PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026Headache The Journal of Head and Face Pain0 citationsOpen Access

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

View Full Paper
SJShivang JoshiCTCristina TassorelliMMManjit Matharu

Key Points

  • This research aims to compare the effectiveness of galcanezumab and traditional oral migraine preventive medications in reducing monthly migraine days.
  • Compared monthly migraine days after 3 months between galcanezumab and TOMP medications
  • Involved adult patients starting or switching to either treatment
  • Patients receiving galcanezumab experienced a greater reduction in monthly migraine days than those on TOMP medications
  • The findings suggest that galcanezumab may be more effective in real-world scenarios

Abstract

Limited information exists on how the use of traditional oral migraine preventive (TOMP) medications compares to the effectiveness of galcanezumab. In this study, we compared the reduction in monthly migraine days after 3 months among adult patients initiating or switching to either a TOMP medication or galcanezumab. Patients receiving galcanezumab had a greater response after 3 months than those receiving TOMP medications, suggesting better real-world effectiveness of galcanezumab.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Joshi et al. (2026) studied this question.

synapsesocial.com/papers/69eb08ef553a5433e34b39d2https://doi.org/10.1111/head.70107
Ask AI
Helpful
Bookmark
Share
View Full Paper